GSK3β is a negative regulator of the transcriptional coactivator MAML1 by Saint Just Ribeiro, Mariana et al.
GSK3b is a negative regulator of the transcriptional
coactivator MAML1
Mariana Saint Just Ribeiro, Magnus L. Hansson, Mikael J. Lindberg,
Anita E. Popko-S ´cibor and Annika E. Wallberg*
Department of Biosciences and Nutrition, Karolinska Institutet, 141 86 Stockholm, Sweden
Received April 14, 2009; Revised August 4, 2009; Accepted August 17, 2009
ABSTRACT
Glycogen synthase kinase 3b (GSK3b) is involved
in several cellular signaling systems through
regulation of the activity of diverse transcription
factors such as Notch, p53 and b-catenin.
Mastermind-like 1 (MAML1) was originally identified
as a Notch coactivator, but has also been reported
to function as a transcriptional coregulator of p53,
b-catenin and MEF2C. In this report, we show that
active GSK3b directly interacts with the MAML1
N-terminus and decreases MAML1 transcriptional
activity, suggesting that GSK3b might target a
coactivator in its regulation of gene expression.
We have previously shown that MAML1 increases
global acetylation of histones, and here we show
that the GSK3 inhibitor SB41, further enhances
MAML1-dependent histone acetylation in cells.
Finally, MAML1 translocates GSK3b to nuclear
bodies; this function requires full-length MAML1
protein.
INTRODUCTION
The protein Mastermind-like 1 (MAML1) (1–3), belongs
to the MAML family that also contains MAML2 and
MAML3 (4,5). The MAML proteins are transcriptional
coactivators for Notch signaling (1–5), an evolutionarily
conserved pathway that plays several key roles in
development and in human disease (6–9). The Notch
ICD (intracellular domain) activates expression of genes
controlled by Notch signaling by interacting with the
conserved DNA-binding protein CSL (10) and recruiting
coactivators such as PCAF, GCN5 (11), p300 (12) and
MAML (1–5). More recently, MAML1 has been shown
to be involved in other cell signaling pathways, and to
function as a coactivator for the tumor suppressor p53
(13), the MADS box transcription enhancer factor
(MEF) 2C (14), and b-catenin (15). The function of
MAML1 as a coactivator for diverse activators also
suggests that MAML1 might be a key molecule that
connects various signaling pathways to regulate cellular
processes in normal cells and in human disease.
MAML1 has been shown to be important for
recruitment of coregulators, such as the histone
acetyltransferase (HAT) p300 (16,17) and the cyclin-
dependent kinase (CDK) 8 (18). Recruitment of CDK8
by MAML1 leads to phosphorylation of Notch1 and
subsequent degradation via the Fbw7/Sel10 ubiquitin
ligase (18). Previous studies reported that MAML1
recruitment of p300 to a DNA-CSL-Notch complex
potentiates Notch ICD transcription from chromatin
templates in vitro (16,17), and the p300-MAML1
complex speciﬁcally acetylates histone H3 and H4 tails
in chromatin in vitro (19). In addition, MAML1
enhances p300 autoacetylation and HAT activity and
this coincides with the translocation of MAML1, p300
and acetylated histones to nuclear bodies (20).
Glycogen synthase kinase 3b (GSK3b) is a multi-
functional kinase found in all eukaryotes, and its activity
is regulated by serine (inhibitory) and tyrosine
(stimulatory) phosphorylation (21,22). GSK3b regulates
many diverse cellular processes including proliferation,
diﬀerentiation and apoptosis (23). Aberrant regulation
of GSK3b has been suggested to be involved in human
diseases such as non-insulin-dependent diabetes mellitus,
cardiovascular and neurodegenerative diseases (23,24).
Transcription factors regulated by GSK3b include
Axin (25,26), b-catenin (27), c-Myc (28,29), NFkB (30),
p53 (31,32) and Notch receptors (33,34). GSK3b
phosphorylation of Notch2 inhibits transcription of the
Notch target gene Hes1. Wnt signaling inhibits GSK3b,
and since overexpression of Wnt upregulates Hes1, it
has been suggested that Notch phosphorylation by
GSK3b regulates cross-talk between the Notch and Wnt
pathways (33).
In this study we have investigated how GSK3b regulates
MAML1 activity. We found that GSK3b inhibits
MAML1 transcriptional activity by directly targeting the
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N-terminus is also crucial for interactions with Notch
(2), p53 (13), MEF2C (14), and p300 (16,19), so we
hypothesize that the N-terminus of MAML1 might be
involved in controlling a possible competition for
MAML1 by diﬀerent signaling pathways. We recently
reported that MAML1 increases global acetylation of
histones (20), and in this paper we show that the GSK3
inhibitor SB41 further enhances MAML1-dependent
acetylation of histone H3 in the cell. We also found that
GSK3b interacts strongly with MAML1 regardless of its
activity status, but that GSK3b must be active to inhibit
MAML1 activity. Finally, we found that MAML1
translocates GSK3b to nuclear bodies, and this requires
the full-length MAML1 protein.
MATERIALS AND METHODS
Plasmids
The expression plasmids pGEX-MAML1 1–1016, 1–300,
309–625, 499–804, 701–1016, pBIND-Notch1 ICD (19),
pBIND-MAML1 1–1016 and 1–300 (20), have been
described previously. cDNAs encoding MAML1 residues
1–127 and 1–200 were ampliﬁed with PCR and subcloned
into pGEX-4T-3. pCDNA-HA-GSK3b WT was a gift
from Dr A. Bigas. pCDNA-HA-GSK3b-S9A (Addgene
plasmid 14754) and pCDNA-HA-GSK3b-K85R
(Addgene plasmid 14755) were generously provided by
Dr J. Woodgett.
Puriﬁcation of proteins and protein interaction assay
GST-tagged proteins were expressed in the Escherichia coli
strain BL21 and puriﬁed with glutathione-Sepharose 4B
(Amersham Biosciences) following manufacturer’s
protocol. In GST-MAML1 interaction assays, 2mgo f
puriﬁed GST-tagged MAML1 proteins, bound to 20ml
of glutathione-Sepharose beads, was incubated with
whole-cell extract from HEK-293 cells transfected with
pCDNA-GSK3b lysed in RIPA buﬀer (25mM Tris–HCl
pH 7.6, 150mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS) and diluted 3 times with
buﬀer A (50mM Tris–HCl, pH 7.5, 150mM KCl, 10%
glycerol, 0.1% NP-40, 1mM DTT and 1mM PMSF)
(Figure 3B) or incubated with HIS-GSK3b (Invitrogen)
and FLAG-Notch1 ICD (as indicated in Figures 1E, 3C
and 5D), expressed in Sf9 (Spodoptera frugiperda) cells via
baculovirus and puriﬁed as described in ref. (17). After
centrifugation of the suspension, the supernatant was
removed and the beads were washed ﬁve times with
500ml of buﬀer A. The proteins were eluted from the
beads, resolved by SDS–PAGE and analyzed by
immunoblot with a monoclonal mouse antibody
recognizing GSK3b (BD Transduction Laboratories).
GST-GSK3b bound to glutathione-Sepharose beads
was incubated with FLAG-MAML1 1–1016 expressed
in Sf9 cells via baculovirus and puriﬁed as described in
ref. (17).
In vitro kinase assay
GST-MAML1 proteins were incubated with recombinant
HIS-GSK3b (puriﬁed from Sf9 cells) in buﬀer B (50mM
Tris–HCl, pH 7.5, 100mM KCl, 10% glycerol, 0.1mg/ml
BSA, 1mM DTT, 1mM PMSF, Phosphatase Inhibitor
Cocktail 2 (Sigma)) containing 100mM cold ATP with
or without 5mCi [g-
32P]ATP at 30C for 30min. The
kinase reactions were separated by SDS–PAGE and
analyzed with autoradiography or staining with Pro-Q
Diamond phosphoprotein staining kit (Invitrogen
P-33301) following manufacturer’s protocol.
Transient transfections and immunoprecipitation
HEK-293 cells or U2OS cells were transiently transfected
in 24-well plates with 20ng Notch1 ICD, 300ng GSK3b,
100ng MAML1 and 100ng of the reporter plasmid
pG5-luc. After 48h, cells were lysed in 250ml Roche lysis
buﬀer and the levels of luciferase were measured.
The bars in Figures 1A, B, 2A, 3F and 5B represent
mean values obtained from at least three independent
experiments. For siRNA transfections, we used
DharmaFECT Duo Transfection Reagent, and pred-
esigned MAML1 SMARTpool set of four siRNA, from
Dharmacon. Protein expression was analyzed by western
blotting using antibodies recognizing MAML1 (Santa
Cruz Biotechnology), Hes1 (Santa Cruz Biotechnology)
and GAPDH (Ambion). For immunoprecipitation
experiments, HEK-293 cells were transfected with
MAML1 using TransIT-LT1 (Mirus). The cells were
harvested 48h after transfection, and lysed in RIPA
buﬀer and aﬃnity-puriﬁcation of MAML1 was performed
with M2-agarose beads (Sigma) (Figure 1C) or MAML1
antibody (Figure 2B). Immunoprecipitated proteins were
analyzed by western blotting using the following
antibodies: MAML1 (Bethyl laboratories), FLAG
(Sigma) and GSK3b (BD Transduction Laboratories). In
addition, C33A cells were lysed in RIPA buﬀer and
endogenous MAML1 immunoprecipitated with an
antibody recognizing MAML1 N-terminus (Santa Cruz
Biotechnology). Immunoprecipitated proteins were
analyzed by western blotting using antibodies recognizing
MAML1 (Santa Cruz Biotechnology) and GSK3b (BD
Transduction Laboratories).
In vivo acetylation assay
HEK-293 cells stably expressing FLAG-MAML1
(f-MAML1 cell line) (20) and control HEK-293 cells
were cultured in the absence or presence of SB41 (e.g.
SB415286) for 24h. The cells were lysed in RIPA lysis
buﬀer and samples were analyzed by western blotting
using the following antibodies: MAML1 (Bethyl
Laboratories), acetylated histone H3 (Ac-H3) (Upstate
Biotechnology), and Tubulin (Santa Cruz Biotechnology).
Immunostaining
Cos7 cells, 60–80% conﬂuent, were transfected with
vectors as indicated in the ﬁgures using TransIT-LT1
transfection reagent (Mirus) After 24h, cells were ﬁxed
with 4% paraformaldehyde, washed with PBS and
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RT. Slides were washed and blocked with 3% BSA
(Sigma) in PBS for an hour at RT. After PBS wash, the
slides were incubated with primary antibodies diluted
in 3% BSA with 0.2% Triton X-100in PBS, overnight
at 4C. Next day, slides were washed four times
and incubated with FITC-conjugated rabbit or Cy3-
conjugated mouse antibodies (Jackson ImmunoResearch
Laboratories) diluted in PBS for 2h at RT. Slides were
washed four times and incubated with 0.1mg/ml DAPI
(Sigma) in PBS for 20s. After three washes with PBS,
slides were mounted with Immuno-Mount medium
(Thermo) and analyzed with ﬂuorescence microscope
coupled with AxioCam digital camera (MRm), using
Axio Vision software (Zeiss).
RESULTS
GSK3b decreases MAML1 transcriptional activity
To investigate if GSK3b regulates MAML1 activity, we
transfected a GAL4 reporter gene with GAL4-MAML1
and GSK3b. As shown in Figure 1A, GAL4-MAML1
activated the reporter gene more than 50-fold, and
expressing GSK3b together with MAML1 decreased
MAML1 activity almost 4-fold. In the presence of the
GSK3 inhibitor SB41, MAML1 transcriptional activation
of the reporter gene (40-fold) was enhanced 3.5-fold
(Figure 1B). Thus, our data suggest that GSK3b might
target a coactivator, such as MAML1, in its regulation
of gene expression. We next investigated if MAML1 and
GSK3b associate in cells. HEK-293 cells were transfected
with a vector expressing FLAG-MAML1, whole-cell
extracts were prepared, and MAML1 protein aﬃnity-
puriﬁed with M2-agarose. As shown in Figure 1C, a
signiﬁcant amount of endogenous GSK3b co-immunopre-
cipitated with MAML1 (compare lanes 1 and 2). In
addition, endogenous MAML1 protein was immunopre-
cipitated from C33A cells with an antibody recognizing
the N-terminus MAML1 (Figure 1D). Endogenous
GSK3b co-immunoprecipitated with MAML1 but not
with the IgG control (compare lanes 2 and 3).
In order to examine if MAML1 directly and indepen-
dently interacts with GSK3b, GST-tagged MAML1 was
GST-MAML1
GST
INPUT
12 3
GSK3β
E
GSK3β
SB41
+ +
+
GST-MAML1 GST
1234
–
+
–
–
–
G
MAML1
INPUT
GST
GST-GSK3β
12 3
F
WB: GSK3β
WB: MAML1
12 3
D
IP:M AML1
IP: Ig G
INPUT
C
IP: FLAG-MAML1
WB: GSK3β
FLAG-MAML1
Neg ctrl
IP: FLAG-MAML1
WB: FLAG
12
WB: GSK3β
+ ++
+
+ SB41
+ –
– –
B
R
e
l
a
t
i
v
e
 
a
c
t
i
v
i
t
y
 
o
f
 
l
u
c
i
f
e
r
a
s
e
pG5-luc
GAL4-MAML1
0
20
40
60
80
100
120
140 A
R
e
l
a
t
i
v
e
 
a
c
t
i
v
i
t
y
 
o
f
 
l
u
c
i
f
e
r
a
s
e
pG5-luc
GAL4-MAML1
GSK3β
+
–
–
–
+
+ + +
+
0
10
20
30
40
50
60
70
+ +
–
Figure 1. GSK3b decreases MAML1 activity. (A) HEK-293 cells were cotransfected with a luciferase reporter containing ﬁve GAL4 binding sites
and vectors expressing GAL4-MAML1 and GSK3b as indicated. (B) GAL4-MAML1 was cotransfected into HEK-293 cells with the luciferase
reporter in the absence or presence of SB41. (C) HEK-293 cells were transfected with a vector expressing FLAG-MAML1, MAML1 was aﬃnity-
puriﬁed with M2-agarose, and proteins separated by SDS–PAGE. Immunoblot detected MAML1, and GSK3b protein that interacted with MAML1.
(D) Endogenous MAML1 protein was immunoprecipitated from C33A cells with an antibody recognizing the N-terminus of MAML1. Proteins were
separated by SDS–PAGE and detection of MAML1, and MAML1-interacting proteins, was monitored by immunoblot with antibodies recognizing
MAML1 and GSK3b.( E) GST-MAML1 and GST coupled to glutathione-Sepharose beads were incubated with aﬃnity-puriﬁed HIS-GSK3b, and
MAML1-interacting GSK3b was monitored by immunoblot. The input represents 10% of GSK3b used in the binding reaction. (F) GST-GSK3b and
GST coupled to glutathione-Sepharose beads were incubated with aﬃnity-puriﬁed FLAG-MAML1, and MAML1 binding to GSK3b was monitored
by immunoblot. The input represents 10% of the MAML1 used in the binding reaction. (G) GSK3b phosphorylates MAML1 in vitro. Recombinant
aﬃnity-puriﬁed proteins HIS-GSK3b, GST-MAML1 or GST, were incubated with [g-
32P]ATP, in the presence or absence of SB41, proteins were
separated by SDS–PAGE and visualized by autoradiography.
Nucleic Acids Research, 2009,Vol.37, No. 20 6693incubated with aﬃnity-puriﬁed HIS-GSK3b. GSK3b
signiﬁcantly interacted with the GST-MAML1 full-
length protein, but not with the GST negative control
(Figure 1E, lanes 2 and 3). Consistently, we found that
GST-GSK3b interacted with aﬃnity-puriﬁed FLAG-
MAML1 (Figure 1F, lane 3). In addition, we performed
an in vitro kinase assay in which GST-MAML1 was
incubated with HIS-GSK3b and [g-
32P]ATP in the
presence or absence of the GSK3 inhibitor SB41 (Figure
1G). GSK3b strongly phosphorylated MAML1 in vitro
(lane 2), and this was inhibited by SB41 (lane 3). Thus,
the in vitro phosphorylation data indicated that MAML1
directly interacts with GSK3b.
GSK3b needs to be active to inhibit MAML1 activity
Phosphorylation of serine 9in GSK3b has been shown to
inactivate GSK3b and the lysine residue K85 is essential
for GSK3b kinase activity. To explore if GSK3b needs
to be in an active state to inhibit MAML1 activity, we
cotransfected a GAL4 reporter gene and GAL4-
MAML1 with GSK3b wild-type (WT), and a vector
expressing GSK3b with serine 9 mutated to an alanine
(GSK3b-S9A), which renders GSK3b constitutively
active. We also used a construct expressing GSK3b with
lysine 85 mutated to an arginine (GSK3b-K85R), which
renders GSK3b kinase-dead. As shown in Figure 2A,
GAL4-MAML1 increased expression of the reporter
gene 26-fold, and both GSK3b WT and GSK3b-S9A
inhibited this activity 5-fold. However, coexpressing
GAL4-MAML1 with the inactive GSK3b-K85R did not
signiﬁcantly aﬀect MAML1 activity, since the levels
of transcription (28-fold), were similar to expressing
GAL-MAML1 alone.
To determine if the activity status of GSK3b aﬀects its
interaction with MAML1 in cell culture, GAL4-MAML1
was cotransfected into HEK-293 cells with vectors
expressing GSK3b WT, GSK3b-S9A or GSK3b-K85R.
Whole-cell extracts were prepared, and MAML1 protein
immunoprecipitated with an antibody recognizing the
MAML1 C-terminus. MAML1, and GSK3b proteins
interacting with MAML1, were detected by western blot,
using antibodies against MAML1 and GSK3b. As shown
in Figure 2B, the GSK3b antibody recognized all GSK3b
proteins equally well (lanes 2–4). Immunoprecipitated
MAML1 (lanes 1–4) interacted equally strongly with
GSK3b WT, GSK3b-S9A and GSK3b-K85R (lanes 2–4).
The MAML1 N-terminus is a target of GSK3b
The MAML1 protein comprises various domains, and has
acidic and basic regions (Figure 3A). We examined which
domain(s) in MAML1 interact with GSK3b, and GST-
tagged MAML1 proteins were incubated with whole-cell
extract from HEK-293 cells transfected with HA-GSK3b.
Figure 3B shows that GSK3b signiﬁcantly interacted with
GST-MAML1 full-length protein (lane 3) and MAML1
amino acids 1–300 (lane 4), but not with amino acids
309–625, 499–804, 701–1016 (lanes 5–7) or the GST
negative control (lane 2). We continued to map GSK3b
binding to MAML1 1–300 by incubating GST-tagged
MAML1 domains 1–300, 1–200 and 1–127 with
recombinant aﬃnity-puriﬁed GSK3b. The data in
Figure 3C show that GSK3b interacts equally well with
these MAML1 truncations, suggesting that region 1–127
contains amino acids important for MAML1 binding to
GSK3b. In addition, we performed an in vitro kinase assay
and incubated GST-MAML1 1–1016, 1–300 and 309–625
with aﬃnity-puriﬁed HIS-GSK3b and [g-
32P]ATP.
GSK3b strongly phosphorylated MAML1 1–1016 and
1–300 (Figure 3D, lanes 1 and 2). However, GSK3b did
not signiﬁcantly phosphorylate MAML1 309–625 (lane 3),
499–804 or 701–1016 (data not shown), which are the
regions in MAML1 that do not interact with GSK3b.
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Figure 2. Active GSK3b regulates MAML1 transcription. (A) Vectors expressing GAL4-MAML1 and HA-GSK3b as WT, S9A or K85R, were
cotransfected into HEK-293 cells with a luciferase reporter. (B) Vectors expressing MAML1 and GSK3b were cotransfected into HEK-293 cells as
indicated, whole-cell extracts were prepared, and MAML1 protein immunoprecipitated. Proteins were separated by SDS–PAGE and detection of
MAML1, and MAML1-interacting proteins, was monitored by immunoblot with antibodies recognizing MAML1 and GSK3b.
6694 Nucleic Acids Research, 2009,Vol.37, No. 20GSK3b was then incubated with MAML1 1–300 and
1–127in the presence of cold ATP, and phosphorylation
of MAML1 determined with Pro-Q Diamond phosp-
hoprotein staining. As shown in Figure 3E, GSK3b
phosphorylated both MAML1 1–300 and 1–127. This
indicates that MAML1 1–127 not only contains amino
acids involved in GSK3b binding, but also comprises
amino acid(s) that can be targeted for GSK3b
phosphorylation.
To investigate if GSK3b inhibits the activity of the
MAML1 N-terminus in cellular assays, we cotransfected
cells with a GAL4 reporter gene, GAL4-MAML1 1–1016
or 1–300, and HA-GSK3b. As shown in Figure 3F,
GSK3b decreased the transcriptional activity of both
MAML1 1–1016 and 1–300 4-fold.
MAML1 directs GSK3b to nuclear bodies
The MAML1 full-length protein has previously been
shown to direct MAML1-interacting proteins such as
Notch (2), p300 (16,20) and MEF2C (14) to nuclear
bodies. In order to elucidate if MAML1 translocates
GSK3b to nuclear bodies, Cos7 cells were cotransfected
with HA-GSK3b and FLAG-MAML1 vectors and
immunostained with antibodies recognizing the HA- and
FLAG-tags (Figure 4A). Consistent with previously
published data (16,20) MAML1 1–1016 was present in
nuclear bodies (rows 2 and 3), while MAML1 1–625 and
1–300 were present in the nucleus but not in nuclear
bodies (rows 4–7). In the absence of overexpressed
MAML1, GSK3b seemed to be present mainly in the
cytoplasm, but also appeared in the nucleus (row 1).
When cells were cotransfected with GSK3b and
MAML1 1–1016, MAML1 directed GSK3b to nuclear
bodies (row 3). In cells transfected with GSK3b and
MAML1 1–625 (rows 4 and 5) or MAML1 1–300 (rows
6 and 7), GSK3b was translocated to the nucleus but not
present in nuclear bodies.
To further explore if MAML1 translocates both
active and inactive forms of GSK3b to nuclear bodies,
Cos7 cells were transfected with vectors expressing HA-
GSK3b-S9A or HA-GSK3b-K85R and FLAG-MAML1.
F
R
e
l
a
t
i
v
e
 
a
c
t
i
v
i
t
y
 
o
f
 
l
u
c
i
f
e
r
a
s
e
pG5-luc
GAL4-MAML1 1-1016
GSK3β
+
–
– –
+ + +
+
+
+
+
+
0
20
40
60
80
100
120
140
+
++
+
–
GAL4-MAML1 1-300
–
–
–
1-300
309-625
1-1016
GSK3β ++ +
123
++ +
123
12 345
123 4 5 67
D
A
p300
Notch/CSL
MAML1 1 1016
p53
Basic
Acidic
1016
804
625
300 1
309
499
701
MEF2C
GST-MAML1
200 1
127 1
MAML1
MAML1
B
GSK3β
Input
1-300
309-625
499-804
701-1016
1-1016
GST
Input
GST
GST-MAML1
1-200
1-300
1-127
GST-MAML1
GSK3β
C
GSK3β
1-300
1-127
GST-MAML1
GSK3β
MAML1
MAML1
Marker
72
kDA
E
– –––
Figure 3. GSK3b directly interacts with the MAML1 N-terminus. (A) Schematic diagram of the MAML1 protein. GST-tagged MAML1 proteins as
indicated, were incubated with whole-cell extract from HEK-293 cells transfected with pCDNA-GSK3b (B) or recombinant aﬃnity-puriﬁed GSK3b
(C), and MAML1-interacting GSK3b detected with immunoblot. (D) Recombinant HIS-GSK3b and GST-MAML1 proteins were aﬃnity-puriﬁed
and incubated with [g-
32P]ATP. Proteins were separated by SDS–PAGE and visualized by autoradiography. (E) GST-MAML1 proteins were
incubated with HIS-GSK3b in the presence of cold ATP. The kinase reactions were separated by SDS–PAGE and stained with Pro-Q Diamond
phosphoprotein staining kit. (F) Vectors expressing GSK3b and were cotransfected with a luciferase reporter containing ﬁve GAL4 binding sites into
U2OS cells.
Nucleic Acids Research, 2009,Vol.37, No. 20 6695In the absence of transfected MAML1, GSK3b was
present mainly in the cytoplasm, regardless of its activity
status (Figure 4B, rows 1 and 3). FLAG-MAML1
strongly directed both HA-GSK3b-S9A and HA-
GSK3b-K85R to nuclear bodies, and colocalized with
these proteins (rows 2 and 4). To investigate if endogenous
GSK3b was translocated to nuclear bodies by MAML1,
Cos7 cells were transfected with FLAG-MAML1 or
empty vector. Immunostaining with an antibody recog-
nizing phosphorylated serine 9in GSK (P-S9) showed
that, in the absence of transfected MAML1, GSK3b was
mainly present in the cytoplasm (Figure 4C, row 1).
However, in the presence of transfected MAML1, endo-
genous GSK3b recognized by the P-S9 antibody was
directed to nuclear bodies (row 2).
GSK3b does not inhibit the MAML1-Notch1 ICD
interaction
Since GSK3b has been reported to potentiate or
inhibit the activity of Notch proteins (Discussion), we
decided to investigate how GSK3b aﬀects
MAML1-dependent Notch transcription. First, we trans-
fected Cos7 cells with vectors expressing FLAG-Notch1
ICD, HA-GSK3b-S9A and MAML1, to see if Notch,
MAML1 and active GSK3b colocalize in cells. In the
absence of transfected MAML1, Notch1 ICD was
widely distributed in the nucleus (Figure 5A, rows 1 and
2). When GSK3b-S9A was cotransfected with Notch1
ICD, GSK3b-S9A was directed to the nucleus (compare
Figure 4B, row 1 to Figure 5A, row 2). Expressing
MAML1 together with either Notch1 ICD or GSK3b-
S9A directed Notch1 ICD (Figure 5A, row 3) and
GSK3b-S9A (Figure 4B, row 2) to nuclear bodies. In
Cos7 cells cotransfected with MAML1, Notch1 ICD and
active GSK3b, all colocalized to these nuclear bodies
(Figure 5, row 4).
We next cotransfected HEK-293 cells with a plasmid
containing ﬁve GAL4 sites upstream of a luciferase gene
and vectors expressing GAL4-Notch1 ICD, MAML1
1–1016 and GSK3b. GAL4-Notch1 ICD activated the
reporter gene 5-fold, and the level of transactivation by
Notch decreased almost 5-fold when cotransfected with
GSK3b (Figure 5B). When we cotransfected MAML1
together with Notch, the levels of transcription were
enhanced more than 15-fold, and expressing GSK3b
together with Notch and MAML1 decreased the Notch
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Figure 4. MAML1 directs GSK3b to nuclear bodies. (A) Vectors expressing FLAG-MAML1 domains as indicated, and HA-GSK3b were
cotransfected into Cos7 cells, and after 24h the cells were immunostained with antibodies recognizing the FLAG- and HA-tags. (B) Vectors
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with antibodies recognizing the FLAG- and HA-tags. (C) Cos7 cells were transfected with FLAG-MAML1 (or empty vector) and immunostained
after 24h with antibodies recognizing the FLAG-tag, and endogenous GSK3b phosphorylated at serine 9 (P-S9).
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assay, GSK3b inhibits Notch1 ICD activity to the same
extent in both the presence and absence of overexpressed
MAML1. The GSK3 inhibitor LiCl has previously been
reported to increase the mRNA levels of the Notch target
gene Hes1 (33). Consistently, we found that expression of
Hes1 protein was signiﬁcantly potentiated in C33A cells
cultured with SB41 (Figure 5C, compare lanes 3 and 4).
When MAML1 expression was eliminated by MAML1
speciﬁc siRNA treatment, C33A cells expressed equally
low levels of Hes1 in the absence or presence of SB41
(lanes 1 and 2), indicating that SB41-dependent increase
in Hes1 protein levels might be dependent on the presence
of MAML1.
We wanted to determine if GSK3b aﬀects the interac-
tion between MAML1 and Notch, and incubated
GST-MAML1 with aﬃnity-puriﬁed HIS-GSK3b and
FLAG-Notch1 ICD, expressed in Sf9 cells via baculo-
virus. Figure 5D shows that GST-MAML1 interacted
strongly, both in the absence or presence of ATP, with
Notch1 ICD (lanes 3 and 6) and with GSK3b (lanes 4
and 7). GST-MAML1 interacted equally well with
Notch and GSK when these three proteins were incubated
together (compare lanes 5 and 8 to lanes 3–4 and 6–7).
Furthermore, phosphorylation of MAML1 by GSK3b
(in the presence of ATP) did not seem to aﬀect MAML1
binding to GSK3b or Notch (compare lane 8 to lane 5).
GSK3 inhibits MAML1-dependent global histone
acetylation
We previously reported that MAML1 increases global
acetylation of histones in cell culture assay (20). To
further explore if GSK3-mediated inhibition of MAML1
activity aﬀects global acetylation of histones, we cultured
HEK-293 cells and an HEK-293 cell line that stably
expresses FLAG-MAML1 (f-MAML1), with the GSK3
inhibitor SB41. Consistent with our previous report, the
data in Figure 6 show that histone acetylation increased in
f-MAML1 cells (lanes 3 and 4), compared to HEK-293
control cells (lanes 1 and 2). SB41 increased acetylation
of histone H3 signiﬁcantly more in f-MAML1 cells
compared to HEK-293 control cells (lanes 2 and 4). The
expression level of tubulin, which is not an MAML1
target, was similar in both cell lines (lanes 1–4). Thus,
our data indicated that GSK3 might be involved in
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Figure 5. The MAML1-Notch1 ICD interaction is not abolished by GSK3b.( A) Vectors expressing FLAG-Notch1 ICD, HA-GSK3b-S9A and
MAML1 1–1016 were cotransfected into Cos7 cells, and after 24h cells were immunostained with antibodies recognizing the FLAG- or HA-tags or
MAML1. (B) HEK-293 cells were cotransfected with a luciferase reporter containing ﬁve GAL4 binding sites and vectors expressing GAL4-Notch1
ICD, MAML1 and GSK3b.( C) C33A cells were transfected with Notch1 ICD and siRNA MAML1 or control (ctrl) siRNA, and incubated in the
presence or absence of SB41. Expression of MAML1, GAPDH and the Notch target gene Hes1 was analyzed with immunoblot with antibodies
recognizing MAML1, Hes1 and GAPDH. (D) GST-MAML1 and GST were incubated, in the presence or absence of ATP, with aﬃnity-puriﬁed
HIS-GSK3b and FLAG-Notch1 ICD proteins as indicated, and MAML1-interacting proteins were detected with immunoblot.
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DISCUSSION
GSK3b, originally identiﬁed as a kinase that phosphor-
ylates glycogen synthase, has been shown to phosphor-
ylate, and regulate the activity of, many diverse proteins
involved in several signaling pathways such as b-catenin,
p53 and Notch (27,31–34). In this study we showed that
GSK3b directly interacts with and decreases the activity
of MAML1, which is a coactivator of Notch, p53 and
b-catenin, (1–3,13,15). MAML1 interacted equally well
with both the active and inactive states of GSK3b in a
cellular assay, but GSK3b must be active to decrease
MAML1 transcriptional activity. Thus, our data suggest
that GSK3b might aﬀect diverse signaling systems by
targeting a coactivator involved in these pathways.
Inhibition of MAML1 activity by GSK3b required the
N-terminus of MAML1, supporting the importance for
this region, since the MAML1 N-terminus is reported to
interact with Notch, p53, and MEF2C, and to play an
important role in the transcription activity of these
factors. Moreover, the MAML1 N-terminus has been
shown to interact with histones (19) and p300 (16,17),
and the MAML1 interaction with p300 increases p300
autoacetylation and HAT activity (although this requires
the full-length MAML1 protein) (20). We therefore
hypothesize that the N-terminus of MAML1 is involved
in controlling the function of MAML1 in various
signaling pathways, which might include the action of
GSK3b. This does not necessarily include a physical
competition for MAML1 between MAML1-interacting
proteins. We found that GSK3b and Notch1 ICD do
not seem to compete for MAML1 binding in cell culture
assay or in vitro binding assay, and GSK3b phosphor-
ylation of MAML1 and Notch1 ICD does not appear to
aﬀect the interaction between these proteins (Figure 5).
Although GSK3b, MAML1 and Notch all colocalize in
the same nuclear bodies, and these proteins do not seem to
compete for binding to each other, it remains to be
determined if GSK3b targets Notch and MAML1
individually, or targets a Notch-MAML1 complex, to
regulate expression of genes.
MAML1 has been suggested to be phosphorylated
(35), although no speciﬁc kinase has been shown to use
MAML1 as a substrate. In this paper, we show that
GSK3b phosphorylates amino acids within MAML1
1–300, in vitro. However, it will be crucial to identify
amino acids in MAML1 that are targets for GSK3b
phosphorylation, and to show that GSK3b can
phosphorylate MAML1 in vivo. Since GSK3b prefers
prior phosphorylation of its substrates, MAML1 is
likely to be phosphorylated in vivo by another kinase.
CDK8 is a kinase that is recruited by MAML1 to phos-
phorylate Notch, which facilitates Notch proteosomal
degradation (18), so CDK8 could be involved in phos-
phorylating MAML1. So far, phosphorylation of Notch
proteins has been correlated with Notch nuclear trans-
location (36,37), cellular transformation (38,39), and
both activation (34) and inhibition (33) of Notch
activity. A previous study demonstrated that GSK3b
phosphorylates Notch1 ICD in vitro, Notch1 signaling is
reduced in GSK3b deﬁcient ﬁbroblasts, and inhibition of
endogenous GSK3b reduces the stability of Notch (34).
Another report describes GSK3b phosphorylation of
Notch2 ICD as negatively regulating Notch trans-
criptional activity (33). In addition, it was recently
reported that Notch1 ICD can be negatively regulated
by the GSK3a isoform (40). This study focused on
GSK3b, and it remains to be explored if GSK3a plays a
role in regulating MAML1 activity.
We found that MAML1 translocates GSK3b to nuclear
bodies in the cell, and the GSK3b translocation requires
the MAML1 full-length protein. Fryer and colleagues
(16), and our previous work (20), showed that MAML1
full-length protein induces translocation of p300 to
nuclear bodies, and that MAML1 protein contains a
C-terminal region that is important for in vivo trans-
criptional activation. The MAML1 C-terminal amino
acids 625–1016 appear to be important for MAML1
translocation of MAML1-interacting proteins to nuclear
bodies, since MAML1 1–625 does not translocate p300
(20) or GSK3b (Figure 4) to nuclear bodies. Nuclear
bodies are found in the nuclei of various cells, and are
suggested to be involved in various cellular functions,
such as transcriptional regulation and chromatin
organization, post-translational modiﬁcations of proteins
and identiﬁcation and storage of proteins. In our cell
culture assay MAML1 translocates both inactive and
active GSK3b to nuclear bodies, and we speculate that
nuclear bodies might act as an intracellular storage
pool of GSK3b protein. In the absence of cotransfected
MAML1 or Notch, GSK3b is mainly present in
the cytoplasm. We showed that constitutively active
GSK3b-S9A protein, can be translocated by Notch1
ICD to the nucleus (Figure 5), and this is in agreement
with a previous study showing that Notch2 ICD
translocates GSK3b WT to the nucleus (33).
Interestingly, while MAML1 1–1016 translocates GSK3b
to nuclear bodies, MAML1 1–625 and 1–300 translocate
GSK3b to the nucleus, indicating that perhaps two regions
in MAML1 are involved in translocating proteins in
Ac-H3
MAML1
Tubulin
34 12
f-MAML1
+ SB41 – +
ctrl cell line
–
Figure 6. GSK3b inhibits MAML1-dependent global histone
acetylation. f-MAML1 or HEK-293 cells (ctrl cell line), were incubated
in the presence or absence of SB41. The levels of expressed MAML1,
acetylated histone H3 (Ac-H3), and tubulin, were monitored with
immunoblot.
6698 Nucleic Acids Research, 2009,Vol.37, No. 20the cell. The N-terminus of MAML1 (aa 1–300) appears
to comprise a region that directs translocation of
cytoplasmic GSK3b to the nucleus, while the MAML1
C-terminus (aa 625–1016) has a region that is crucial for
translocation to nuclear bodies.
We found that the speciﬁc GSK3 inhibitor SB41 signiﬁ-
cantly increases MAML1 activity in cellular cultures,
indicating that MAML1 is most likely inhibited by
endogenous GSK3. Furthermore, GSK3b appeared to
interfere with MAML1-dependent global acetylation of
histones. Cell immunostaining revealed that endogenous
GSK3b and MAML1 associate in nuclear bodies, and
we also found that GSK3b and MAML1 interact in
cells when both proteins are present at physiological
concentrations. Future studies will focus on elucidating
the MAML1 mechanism for transporting GSK3b to
nuclear bodies, and the GSK3b function in these cellular
structures.
ACKNOWLEDGEMENT
Dr A. Bigas and Dr J. Woodgett are acknowledged for the
gifts of expression plasmids described in the ‘Materials
and methods’ section.
FUNDING
Swedish Research Council, the Swedish Cancer Society
and the Swedish Children’s Cancer Foundation grants to
A.E.W; fellowship from the Swedish Children’s Cancer
Foundation to M.J.L. Funding for open access charge:
The Swedish Cancer Society.
Conﬂict of interest statement. None declared.
REFERENCES
1. Petcherski,A.G. and Kimble,J. (2000) Mastermind is a putative
activator for Notch. Curr. Biol., 10, R471–R473.
2. Wu,L., Aster,J.C., Blacklow,S.C., Lake,R., Artavanis-Tsakonas,S.
and Griﬃn,J.D. (2000) MAML1, a human homolog of Drosophila
mastermind, is a transcriptional coactivator for NOTCH receptors.
Nat. Genet., 26, 484–489.
3. Kitagawa,M., Oyama,T., Kawashima,T., Yedvobnick,B.,
Kumar,A., Matsuno,K. and Harigaya,K. (2001) A human
protein with sequence similarity to Drosophila mastermind
coordinates the nuclear form of notch and a CSL protein to build
a transcriptional activator complex on target promoters. Mol. Cell
Biol., 21, 4337–4346.
4. Lin,S.E., Oyama,T., Nagase,T., Harigaya,K. and Kitagawa,M.
(2002) Identiﬁcation of new human mastermind proteins deﬁnes
a family that consists of positive regulators for notch signaling.
J. Biol. Chem., 277, 50612–50620.
5. Wu,L., Sun,T., Kobayashi,K., Gao,P. and Griﬃn,J.D. (2002)
Identiﬁcation of a family of mastermind-like transcriptional
coactivators for mammalian notch receptors. Mol. Cell Biol., 22,
7688–7700.
6. Artavanis-Tsakonas,S., Rand,M.D. and Lake,R.J. (1999) Notch
signaling: cell fate control and signal integration in development.
Science, 284, 770–776.
7. Borggrefe,T. and Oswald,F. (2009) The Notch signaling pathway:
transcriptional regulation at Notch target genes. Cell Mol. Life. Sci.
8. Bray,S.J. (2006) Notch signaling: a simple pathway becomes
complex. Nat. Rev. Mol. Cell Biol., 7, 678–689.
9. Talora,C., Campese,A.F., Bellavia,D., Felli,M.P., Vacca,A.,
Gulino,A. and Screpanti,I. (2008) Notch signaling and diseases:
an evolutionary journey from a simple beginning to complex
outcomes. Biochim. Biophys. Acta, 1782, 489–497.
10. Fortini,M.E. and Artavanis-Tsakonas,S. (1994) The suppressor of
hairless protein participates in notch receptor signaling. Cell, 79,
273–282.
11. Kurooka,H. and Honjo,T. (2000) Functional interaction between
the mouse notch1 intracellular region and histone acetyltransferases
PCAF and GCN5. J. Biol. Chem., 275, 17211–17220.
12. Oswald,F., Tauber,B., Dobner,T., Bourteele,S., Kostezka,U.,
Adler,G., Liptay,S. and Schmid,R.M. (2001) p300 acts as a
transcriptional coactivator for mammalian Notch1. Mol. Cell Biol.,
21, 7761–7774.
13. Zhao,Y., Katzman,R.B., Delmolino,L.M., Bhat,I., Zhang,Y.,
Gurumurthy,C.B., Germaniuk-Kurowska,A., Reddi,H.V.,
Solomon,A., Zeng,M.S. et al. (2007) The notch regulator MAML1
interacts with p53 and functions as a coactivator. J. Biol. Chem.,
282, 11969–11981.
14. Shen,H., McElhinny,A.S., Cao,Y., Gao,P., Liu,J., Bronson,R.,
Griﬃn,J.D. and Wu,L. (2006) The Notch coactivator, MAML1,
functions as a novel coactivator for MEF2C-mediated transcription
and is required for normal myogenesis. Genes Dev., 20, 675–688.
15. Alves-Guerra,M.C., Ronchini,C. and Capobianco,A.J. (2007)
Mastermind-like 1 Is a speciﬁc coactivator of beta-catenin
transcription activation and is essential for colon carcinoma cell
survival. Cancer Res., 67, 8690–8698.
16. Fryer,C.J., Lamar,E., Turbachova,I., Kintner,C. and Jones,K.A.
(2002) Mastermind mediates chromatin-speciﬁc transcription and
turnover of the Notch enhancer complex. Genes Dev., 16,
1397–1411.
17. Wallberg,A.E., Pedersen,K., Lendahl,U. and Roeder,R.G. (2002)
p300 and PCAF act cooperatively to mediate transcriptional
activation from chromatin templates by notch intracellular domains
in vitro. Mol. Cell Biol., 22, 7812–7819.
18. Fryer,C.J., White,J.B. and Jones,K.A. (2004) Mastermind recruits
CycC:CDK8 to phosphorylate the Notch ICD and coordinate
activation with turnover. Mol. Cell, 16, 509–520.
19. Saint Just Ribeiro,M., Hansson,M.L. and Wallberg,A.E. (2007)
A proline repeat domain in the Notch coactivator MAML1 is
important for the p300-mediated acetylation of MAML1. Biochem.
J., 404, 289–298.
20. Hansson,M.L., Popko-Scibor,A.E., Saint Just Ribeiro,M.,
Dancy,B.M., Lindberg,M.J., Cole,P.A. and Wallberg,A.E. (2009)
The transcriptional coactivator MAML1 regulates p300
autoacetylation and HAT activity. Nucleic Acids Res., 37,
2996–3006.
21. Frame,S. and Cohen,P. (2001) GSK3 takes centre stage more than
20 years after its discovery. Biochem. J., 359, 1–16.
22. Kockeritz,L., Doble,B., Patel,S. and Woodgett,J.R. (2006)
Glycogen synthase kinase-3 – an overview of an over-achieving
protein kinase. Curr. Drug Targets, 7, 1377–1388.
23. Force,T. and Woodgett,J.R. (2009) Unique and overlapping
functions of GSK-3 isoforms in cell diﬀerentiation and proliferation
and cardiovascular development. J. Biol. Chem., 284, 9643–9647.
24. Cohen,P. and Frame,S. (2001) The renaissance of GSK3. Nat. Rev.
Mol. Cell Biol., 2, 769–776.
25. Ikeda,S., Kishida,S., Yamamoto,H., Murai,H., Koyama,S. and
Kikuchi,A. (1998) Axin, a negative regulator of the Wnt signaling
pathway, forms a complex with GSK-3beta and beta-catenin and
promotes GSK-3beta-dependent phosphorylation of beta-catenin.
EMBO J., 17, 1371–1384.
26. Yamamoto,H., Kishida,S., Kishida,M., Ikeda,S., Takada,S. and
Kikuchi,A. (1999) Phosphorylation of axin, a Wnt signal negative
regulator, by glycogen synthase kinase-3beta regulates its stability.
J. Biol. Chem., 274, 10681–10684.
27. Yost,C., Torres,M., Miller,J.R., Huang,E., Kimelman,D. and
Moon,R.T. (1996) The axis-inducing activity, stability, and
subcellular distribution of beta-catenin is regulated in Xenopus
embryos by glycogen synthase kinase 3. Genes Dev., 10, 1443–1454.
28. Pulverer,B.J., Fisher,C., Vousden,K., Littlewood,T., Evan,G. and
Woodgett,J.R. (1994) Site-speciﬁc modulation of c-Myc
cotransformation by residues phosphorylated in vivo. Oncogene, 9,
59–70.
Nucleic Acids Research, 2009,Vol.37, No. 20 669929. Sears,R., Nuckolls,F., Haura,E., Taya,Y., Tamai,K. and
Nevins,J.R. (2000) Multiple Ras-dependent phosphorylation
pathways regulate Myc protein stability. Genes Dev., 14, 2501–2514.
30. Hoeﬂich,K.P., Luo,J., Rubie,E.A., Tsao,M.S., Jin,O. and
Woodgett,J.R. (2000) Requirement for glycogen synthase
kinase-3beta in cell survival and NF-kappaB activation. Nature,
406, 86–90.
31. Watcharasit,P., Bijur,G.N., Song,L., Zhu,J., Chen,X. and Jope,R.S.
(2003) Glycogen synthase kinase-3beta (GSK-3beta) binds to and
promotes the actions of p53. J. Biol. Chem., 278, 48872–48879.
32. Turenne,G.A. and Price,B.D. (2001) Glycogen synthase kinase3
beta phosphorylates serine 33 of p53 and activates p53’s
transcriptional activity. BMC Cell Biol., 2, 12.
33. Espinosa,L., Ingles-Esteve,J., Aguilera,C. and Bigas,A. (2003)
Phosphorylation by glycogen synthase kinase-3 beta down-regulates
Notch activity, a link for Notch and Wnt pathways. J. Biol. Chem.,
278, 32227–32235.
34. Foltz,D.R., Santiago,M.C., Berechid,B.E. and Nye,J.S. (2002)
Glycogen synthase kinase-3beta modulates notch signaling and
stability. Curr. Biol., 12, 1006–1011.
35. Jeﬀries,S., Robbins,D.J. and Capobianco,A.J. (2002)
Characterization of a high-molecular-weight Notch complex in the
nucleus of Notch(ic)-transformed RKE cells and in a human T-cell
leukemia cell line. Mol. Cell Biol., 22, 3927–3941.
36. Redmond,L., Oh,S.R., Hicks,C., Weinmaster,G. and Ghosh,A.
(2000) Nuclear Notch1 signaling and the regulation of dendritic
development. Nat. Neurosci., 3, 30–40.
37. Shimizu,K., Chiba,S., Hosoya,N., Kumano,K., Saito,T.,
Kurokawa,M., Kanda,Y., Hamada,Y. and Hirai,H. (2000) Binding
of Delta1, Jagged1, and Jagged2 to Notch2 rapidly induces
cleavage, nuclear translocation, and hyperphosphorylation of
Notch2. Mol. Cell Biol., 20, 6913–6922.
38. Chiang,M.Y., Xu,M.L., Histen,G., Shestova,O., Roy,M., Nam,Y.,
Blacklow,S.C., Sacks,D.B., Pear,W.S. and Aster,J.C. (2006)
Identiﬁcation of a conserved negative regulatory sequence that
inﬂuences the leukemogenic activity of NOTCH1. Mol. Cell Biol.,
26, 6261–6271.
39. Ronchini,C. and Capobianco,A.J. (2000) Notch(ic)-ER
chimeras display hormone-dependent transformation, nuclear
accumulation, phosphorylation and CBF1 activation. Oncogene, 19,
3914–3924.
40. Jin,Y.H., Kim,H., Oh,M., Ki,H. and Kim,K. (2009) Regulation
of Notch1/NICD and Hes1 expressions by GSK-3alpha/beta.
Mol. Cells, 27, 15–19.
6700 Nucleic Acids Research, 2009,Vol.37, No. 20